Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EBITDA (2016 - 2025)

BioCorRx (BICX) has disclosed EBITDA for 16 consecutive years, with -$5.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 350.08% to -$5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.3 million through Dec 2025, down 82.56% year-over-year, with the annual reading at -$4.8 million for FY2025, 5.38% up from the prior year.
  • EBITDA hit -$5.0 million in Q4 2025 for BioCorRx, down from -$1.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$816292.0 in Q4 2023 to a low of -$5.0 million in Q4 2025.
  • Historically, EBITDA has averaged -$1.4 million across 5 years, with a median of -$1.1 million in 2022.
  • Biggest five-year swings in EBITDA: soared 55.51% in 2021 and later tumbled 350.08% in 2025.
  • Year by year, EBITDA stood at -$1.3 million in 2021, then rose by 11.08% to -$1.2 million in 2022, then surged by 30.78% to -$816292.0 in 2023, then tumbled by 36.23% to -$1.1 million in 2024, then crashed by 350.08% to -$5.0 million in 2025.
  • Business Quant data shows EBITDA for BICX at -$5.0 million in Q4 2025, -$1.9 million in Q3 2025, and -$1.4 million in Q2 2025.